|
🦁
|
The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study
C. Hay,
C. Négrier,
C. Ludlam
|
8 |
1997 |
8
🦁
|
|
🦁
|
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation
C. Hay,
S. Brown,
P. Collins,
D. Keeling,
R. Liesner
|
8 |
2006 |
8
🦁
|
|
🐢
|
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99
8 auth.
S. Darby,
D. Keeling,
R. Spooner,
S. Wan Kan,
P. Giangrande,
P. Collins,
...
F. Hill,
C. Hay
|
7 |
2004 |
7
🐢
|
|
🦁
|
Factor VIII Inhibitors in Mild and Moderate-severity Haemophilia A
14 auth.
C. Hay,
C. Ludlam,
B. Colvin,
F. Hill,
F. Preston,
N. Wasseem,
R. Bagnall,
I. Peake,
E. Berntorp,
E. Bunschoten,
...
K. Fijnvandraat,
C. Kasper,
G. White,
E. Santagostino
|
7 |
1998 |
7
🦁
|
|
🐢
|
Development of resistance to activated protein C during pregnancy
A. Cumming,
R. Tait,
S. Fildes,
A. Yoong,
S. Keeney,
C. Hay
|
7 |
1995 |
7
🐢
|
|
🐜
|
Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
15 auth.
P. Chowdary,
S. Lethagen,
S. Lethagen,
U. Friedrich,
B. Brand,
C. Hay,
F. A. Karim,
R. Klamroth,
P. Knoebl,
M. Laffan,
...
J. Mahlangu,
Wolfgang A Miesbach,
J. Nielsen,
M. Martin-Salces,
P. Angchaisuksiri
|
7 |
2015 |
7
🐜
|
|
🦁
|
HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A
10 auth.
C. Hay,
W. Oilier,
L. Pepper,
A. Cumming,
S. Keeney,
A. Goodeve,
...
B. Colvin,
F. Hill,
F. Preston,
I. Peake
|
7 |
1997 |
7
🦁
|
|
🐢
|
The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population
A. Cumming,
S. Keeney,
A. Salden,
M. Bhavnani,
K. Shwe,
C. Hay
|
7 |
1997 |
7
🐢
|
|
🐢
|
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
8 auth.
P. Collins,
E. Chalmers,
D. Hart,
R. Liesner,
S. Rangarajan,
K. Talks,
...
Mike Williams,
C. Hay
|
7 |
2013 |
7
🐢
|
|
🐜
|
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1
13 auth.
M. Tarantino,
Peter W. Collins,
C. Hay,
A. Shapiro,
R. Gruppo,
E. Berntorp,
G. Bray,
S. Tonetta,
P. Schroth,
A. Retzios,
...
S. Rogy,
M. Sensel,
B. Ewenstein
|
7 |
2004 |
7
🐜
|
|
🐜
|
Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII
14 auth.
M. Recht,
L. Nemes,
M. Matysiak,
M. Manco‐Johnson,
J. Lusher,
M. Smith,
P. Mannucci,
C. Hay,
T. Abshire,
A. O’Brien,
...
B. Hayward,
C. Udata,
D. Roth,
S. Arkin
|
6 |
2009 |
6
🐜
|
